

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Proposed Single Technology Appraisal (STA)**

**Rivaroxaban for the treatment and long term secondary prevention of venous thromboembolism**

**Provisional matrix of consultees and commentators (pre-referral)**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Bayer (rivaroxaban)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Anticoagulation Europe</li> <li>• Black Health Agency</li> <li>• British Lung Foundation</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• DVT Awareness Campaign</li> <li>• Equalities National Council</li> <li>• Lifeblood: The Thrombosis Charity</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Anticoagulation Specialist Association</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for Service to the Elderly</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Orthopaedic Association</li> <li>• British Society for Haematology</li> <li>• British Society for Haemostasis and Thrombosis</li> <li>• British Thoracic Society</li> <li>• British Vein Institute</li> <li>• Clinical Leaders of Thrombosis (CLOT)</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• NHS Quality Improvement Scotland</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (warfarin)</li> <li>• Alliance Pharmaceuticals (acenocoumarol)</li> <li>• Archimedes Pharma (bemiparin)</li> <li>• Arrow Generics (warfarin)</li> <li>• Baxter Healthcare (heparin sodium)</li> <li>• Boehringer-Ingelheim (dabigatran)</li> <li>• Bristol Laboratories (warfarin)</li> <li>• Bristol-Myers Squibb (warfarin)</li> <li>• Goldshield Pharmaceuticals (warfarin,phenindione)</li> <li>• Kent Pharmaceuticals (warfarin)</li> <li>• Leo Pharma (heparin sodium,</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of rivaroxaban for the treatment and long term secondary prevention of venous thromboembolism

Issue date: August 2010

## Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Society of Medicine</li> <li>• Society for Vascular Technology</li> <li>• Society of Vascular Nurses</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• Vascular Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Haringey</li> <li>• Torbay Care NHS Trust</li> <li>• Welsh Assembly Government</li> </ul>	<p>tinzaparin)</p> <ul style="list-style-type: none"> <li>• Mylan (warfarin)</li> <li>• Pfizer (dalteparin)</li> <li>• Sandoz (warfarin)</li> <li>• Sanofi- Aventis (enoxaparin)</li> <li>• Teva UK (warfarin)</li> <li>• The Boots company (warfarin)</li> <li>• Winthrop Pharmaceuticals (warfarin)</li> <li>• Wockhardt (heparin sodium)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Antithrombotic Trialists' (ATT) Collaboration</li> <li>• Cochrane Peripheral Vascular Disease Group</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> <li>• Thrombosis Research Institute</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Acute Care</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important

organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.